FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL	
OMB Number:	3235-0	287
Estimated average	burden	
nours per response	e	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person * Newell Joe				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 05/18/2021								X Officer (give title below) Other (specify below) Chief Operations Officer					
SOUTH	SAN FRA	(Street)	CA 94080	4. If A	Amendn	nent,	Date	Origii	nal F	iled(Mont	h/Day/Yea	ar)		X_Form file	ed by One Repo	Group Filing rting Person One Reporting	• •	ble Line)
(City	')	(State)	(Zip)			Ta	able I	- Non	ı-Dei	ivative	Securiti	ies Ac	equir	red, Dispo	sed of, or I	Beneficially	Owned	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	Execu- any	Deemed ution Date, if	Code (Instr. 8)		tion	4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5)		D) Beneficia Reported		ant of Securities ially Owned Following d Transaction(s)		6. Ownership Form:	Beneficial			
			(Month/Day/Year)			ode	V	Amoun	(A) or (D)	Prio		(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common	Stock		05/18/2021				S	1)		2,453	D	\$ 14.5 (2)	55	128,971			D	
			or each class of secu	Deriva	tive Sec	curit	ies Ac	equire	Pers cont the t	ons whatained ifform dis	no resp n this f splays of, or B	form a cu	are rrent	not requ tly valid		ormation spond unle rol numbe	ss	1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	Execution D v/Year) any	4. Transaction Code Year) (Instr. 8)		5.		and Expiration Date (Month/Day/Year)		7. Tit Amou Inde	cle and unt of crlying rities : 3 and		9. Number o Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Benefici Ownersh (Instr. 4)			
					Code	V	(A)	(D)	Date		Expirat Date	tion T	Γitle	Amount or Number of Shares				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Newell Joe C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080			Chief Operations Officer					

Signatures

/s/ David Tucker, Attorney-in-Fact for Joe Newell	05/20/2021
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
- (2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.